EUVIMEDEUVIMED entdecken
Crossref

The potential role of emicizumab prophylaxis in severe von Willebrand disease

Assaf A Barg, Einat Avishai, Ivan Budnik, Tamar Barazani Brutman, Ilia Tamarin, Rima Dardik, Dalia Bashari, Mudi Misgav, Aharon Lubetsky, Shadan Lalezari, Tami Livnat, Gili Kenet

Blood Cells, Molecules, and Diseases · 2021-03 · 87 · 102530

DOI: 10.1016/j.bcmd.2020.102530 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Blood Cells, Molecules, and Diseases, 2021-03. Verfasst von Assaf A Barg und 11 weiteren Autor:innen. Beteiligte Einrichtung: National Hemophilia Center, Sheba Medical center, Tel Hashomer, Israel; Amalia Biron Research Institute of Thrombosis and Hemostasis, Sackler School …. Die Arbeit wurde bisher 32-mal zitiert (Crossref) und nennt 30 Literaturangaben. Gefördert von: Roche.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AdolescentAdultAntibodies, BispecificAntibodies, Monoclonal, HumanizedBlood CoagulationChildFemaleHemarthrosisHemostasisHumansMaleThrombinYoung Adultvon Willebrand Diseases

Stichwörter der Autor:innen

ChildrenEmicizumabProphylactic treatmentThrombin generationvon Willebrand disease

Substanzen

Antibodies, BispecificAntibodies, Monoclonal, HumanizedemicizumabThrombin

Autor:innen und Institutionen

  • National Hemophilia Center, Sheba Medical center, Tel Hashomer, Israel; Amalia Biron Research Institute of Thrombosis and Hemostasis, Sackler School of Medicine, Tel Aviv University, Israel.
  • Department of Pathophysiology, Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russia.
  • National Hemophilia Center, Sheba Medical center, Tel Hashomer, Israel.
  • National Hemophilia Center, Sheba Medical center, Tel Hashomer, Israel; Amalia Biron Research Institute of Thrombosis and Hemostasis, Sackler School of Medicine, Tel Aviv University, Israel. Electronic address: gili.ken…

Förderung

  • Roche

Zitieren

APA

Barg, A. A., Avishai, E., Budnik, I., Brutman, T. B., Tamarin, I., Dardik, R., Bashari, D., Misgav, M., Lubetsky, A., Lalezari, S., Livnat, T., & Kenet, G. (2021). The potential role of emicizumab prophylaxis in severe von Willebrand disease. Blood Cells, Molecules, and Diseases, 87, 102530. https://doi.org/10.1016/j.bcmd.2020.102530

Vancouver

Barg AA, Avishai E, Budnik I, Brutman TB, Tamarin I, Dardik R, et al. The potential role of emicizumab prophylaxis in severe von Willebrand disease. Blood Cells, Molecules, and Diseases. 2021;87:102530. doi:10.1016/j.bcmd.2020.102530

BibTeX
@article{Barg2021,
  author = {Barg, Assaf A and Avishai, Einat and Budnik, Ivan and Brutman, Tamar Barazani and Tamarin, Ilia and Dardik, Rima and Bashari, Dalia and Misgav, Mudi and Lubetsky, Aharon and Lalezari, Shadan and Livnat, Tami and Kenet, Gili},
  title = {The potential role of emicizumab prophylaxis in severe von Willebrand disease},
  journal = {Blood Cells, Molecules, and Diseases},
  year = {2021},
  volume = {87},
  pages = {102530},
  doi = {10.1016/j.bcmd.2020.102530}
}
Kostenlos starten →